Herbert R. Henney

Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial

Andrew I.R. Maas, Gordon Murray, Herbert R. Henney et al. · The Lancet Neurology · 2005 · 278 citations

Cannabis Use, Traumatic Brain Injury, Brain Injury Medicine +11

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials

Andrew Goodman, François Béthoux, Theodore R. Brown et al. · Multiple Sclerosis Journal · 2015 · 51 citations · Full text

Single‐Dose Pharmacokinetics of Sustained‐Release Fampridine (Fampridine‐SR) in Healthy Volunteers and Adults With Renal Impairment

William B. Smith, Suzanne K. Swan, Thomas Marbury et al. · The Journal of Clinical Pharmacology · 2009 · 40 citations

Potassium Channel Blocker, Urology, Renal Function +15

Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: A phase I–II, open-label trial

Timothy R. Vollmer, Herbert R. Henney · Clinical Therapeutics · 2009 · 39 citations

Open-label Trial, Therapeutic Drug Monitoring, Clinical Therapeutic +8

Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-Release 10-mg tablets in patients with multiple sclerosis: A 2-week, open-label, follow-up study

Timothy Vollmer, Andrew R. Blight, Herbert R. Henney · Clinical Therapeutics · 2009 · 38 citations

Therapeutic Drug Monitoring, Follow-up Study, Medicine +7